Director William R. Enquist, Jr. resigns from Ra Medical board effective Dec 31, 2021

Catheter Precision, Inc.

Enquist resigned due to California board gender diversity law (Corp. Code §301.3); no disagreement with company.
Compensation Committee after resignation: Martin Colombatto (Chair) and Susanne L. Meline.
Board appointed Colombatto to Nominating and Corporate Governance Committee, now: Joan Stafslien (Chair) and Colombatto.
Audit Committee unchanged: Richard Mejia, Jr. (Chair) and Joan Stafslien; all committee members independent per NYSE American.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

William R. Enquist, Jr.

Director

VTAK · Catheter Precision, Inc.

Effective: 2021-12-31
Filed: December 23, 2021, 6:59 PM ET

On December 17, 2021, William R. Enquist, Jr. notified Ra Medical Systems, Inc. (the “Company”) that, effective December 31, 2021, he is resigning from the Company’s Board of Directors (the “Board”) as well as from the Nominating and Corporate Governance Committee and the Compensation Committee.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

William R. Enquist, Jr. resigned as Director at Catheter Precision, Inc..

Action: resigned
Role: Director

Exact text from the filing

On December 17, 2021, William R. Enquist, Jr. notified Ra Medical Systems, Inc. (the “Company”) that, effective December 31, 2021, he is resigning from the Company’s Board of Directors (the “Board”) as well as from the Nominating and Corporate Governance Committee and the Compensation Committee.

View on SEC.gov

Catheter Precision, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-21-061150

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.